СРАВНИТЕЛЬНАЯ ОЦЕНКА ФАРМАКОПЕЙНЫХ ТРЕБОВАНИЙ К ЛЕКАРСТВЕННОМУ РАСТИТЕЛЬНОМУ СЫРЬЮ, СОДЕРЖАЩЕЕ СЕРДЕЧНЫЕ ГЛИКОЗИДЫ

2022

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.26577/eb.2022.v93.i4.03
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Proper assessment of the quality of the obtained phytosubstances from the raw materials under study involves establishing the level of requirements for its quality. In this regard, the aim of the work is to establish the pharmacopoeial level of requirements for the quality of medicinal plant raw materials containing cardiac glycosides, based on the results of a comparative evaluation of pharmacopoeial monographs. 16 pharmacopoeias were used to collect data, of which 4 were homeopathic. The search was performed according to the keywords denoting the names of cardiac glycosides and pharmacopoeia types of medicinal plant raw materials in Latin and the language of pharmacopoeia. Based on the comparative analysis, the main list of quality indicators has been established, taking into account the requirements of national standards, which include: definition; identification, including macro- and microscopy, physico-chemical methods for determining biologically active substances; tests that include the determination of foreign impurities, weight loss during drying, the content of total ash, ash insoluble in hydrochloric acid; quantitative determination; microbiological purity; radionuclides, heavy metals, storage conditions and shelf life. Thus, unified requirements for the quality of medicinal plant raw materials containing cardiac glycosides have been developed, and optimal regulated norms for the main quality indicators have been determined, and their relationship with the quantitative content of cardiac glycosides in raw materials has been established.